TY  - GEN
AU  - Uccelli, Antonio
AU  - Laroni, Alice
AU  - Brundin, Lou
AU  - Clanet, Michel
AU  - Fernandez, Oscar
AU  - Nabavi, Seyed Massood
AU  - Muraro, Paolo A.
AU  - Oliveri, Roberto S.
AU  - Radue, Ernst W.
AU  - Sellner, Johann
AU  - Soelberg Sorensen, Per
AU  - Sormani, Maria Pia
AU  - Wuerfel, Jens Thomas
AU  - Battaglia, Mario. A.
AU  - Freedman, Mark S.
PY  - 2019
DO  - 10.1186/s13063-019-3346-z
UR  - http://hdl.handle.net/20.500.12105/17864
AB  - Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Multiple sclerosis
KW  - Mesenchymal stem cells
KW  - Mesenchymal stromal cells
KW  - Clinical trial
KW  - Esclerosis múltiple
KW  - Células madre mesenquimatosas
KW  - Ensayo clínico
KW  - Adolescent
KW  - Adult
KW  - Clinical Trials, Phase I as Topic
KW  - Clinical Trials, Phase II as Topic
KW  - Cross-Over Studies
KW  - Disability Evaluation
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Mesenchymal Stem Cell Transplantation
KW  - Middle Aged
KW  - Multicenter Studies as Topic
KW  - Multiple Sclerosis
KW  - Randomized Controlled Trials as Topic
KW  - Recovery of Function
KW  - Time Factors
KW  - Transplantation, Autologous
KW  - Treatment Outcome
TI  - MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
TY  - research article
ER  -